External beam radiotherapy otherwise known as teletherapy, is the most frequently used form of radiotherapy. The patient sits or lies on a couch and an external source of radiation is pointed at a particular part of the body. Kilovoltage (also known as, superficial) x-rays are used for treating skin cancer and superficial structures. Megavoltage (or deep) X-rays are used to treat deep-seated tumours (eg bladder, bowel, prostate, lung, brain).
Varian Medical Systems has received FDA 510(k) clearance for the Acuros® XB advanced dose calculation algorithm which can complete a RapidArc® treatment plan two to three times faster than conventional planning algorithms. Varian has incorporated the Acuros algorithm for external beam radiotherapy treatment planning into its market-leading Eclipse™ treatment planning system on exhibit at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego October 31 - November 4.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University of Texas Southwestern and Fox Chase Cancer Center, will be presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego from October 31 to November 4.
Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).
The Department of Radiation Oncology at the University of Alabama at Birmingham Comprehensive Cancer Center is among the world's first to begin using radiation technology that dramatically reduces treatment times.UAB's Hazelrig-Salter Radiation Oncology Center is the third U.S. site to acquire TrueBeam technology. TrueBeam, by Varian Medical Systems Inc., can complete a standard 40-minute radiation therapy in less than a minute for select patients. The precision of the instrument, measured in increments of less than a millimeter, comes from real-time patient imaging, positioning, beam shaping and many other data points synchronized continually as treatment progresses.
The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.
A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.
GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.
Orbital Therapy has completed the build of their proof-of-concept prototype for breast cancer irradiation, and demonstrated the feasibility to develop and operate an external beam radiotherapy device without the use of a heavily shielded bunker infrastructure.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).
TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).
The largest single-institution study of its kind has found few complications in prostate cancer patients treated with radiotherapy after surgery to remove the prostate. Men in this study received radiotherapy after a prostate-specific antigen (PSA) test following surgery indicated their cancer had recurred.
External beam partial breast irradiation (EB-PBI) is the most cost-effective method for treating postmenopausal women with early-stage breast cancer based on utilities, recurrence risks and costs when compared to whole breast radiotherapy (WBRT) and brachytherapy partial breast irradiation (brachy-PBI), according to a study in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).
For men younger than 50 with prostate cancer, undergoing a radical prostatectomy can greatly increase their chances for long-term survival, according to a new study from Henry Ford Hospital.
Quality of life after treatment for endometrial cancer can be significantly improved by the use of vaginal brachytherapy, where radiotherapy is delivered internally using a vaginal cylinder, the European Cancer Conference (ECCO 14).
Quality of life after treatment for endometrial cancer can be significantly improved by the use of vaginal brachytherapy, where radiotherapy is delivered internally using a vaginal cylinder, the European Cancer Conference (ECCO 14) heard today (Monday September 24).
The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).
Obese men with prostate cancer are at higher risk for treatment failure after primary radiation therapy, according to a new study.
Rectourethral fistulas (RUF) are a challenging problem observed by urological and colorectal surgeons.
Salvage radiation therapy to the prostatic fossa is often employed in patients with rising PSA after radical prostatectomy (RP). Interestingly, only 25% of men with rising PSA after RP have a positive prostatic fossa biopsy, yet 70% of men with a negative biopsy will have their PSA decline to undetectable levels following salvage external beam radiotherapy.
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.